Pegcetacoplan is a proximal complement inhibitor indicated for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH). PNH is a rare, acquired condition caused by dysregulation of the complement pathway leading to hemolysis, fatigue, thrombosis, organ dysfunction and bone marrow hypocellularity. This PQI will focus on the role of pegcetacoplan in the management of PNH.